IL2 and neoplasm: The extracted lymphocytes are then expanded in vitro using a culture medium with IL-2, tested for reactivity against autologous tumor cells, selecting the most reactive lymphocytes, and finally incubating them with anti-IL2 and anti-CD3 antibodies before infusion back into the patient.